Evidence map›Paper›PMID 26582898›Full record

ArticleScience translational medicine2015

Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle.

Miles A Miller, Suresh Gadde, Christina Pfirschke, Camilla Engblom, Melissa M Sprachman, Rainer H Kohler, Katherine S Yang, Ashley M Laughney, Gregory Wojtkiewicz, Nazila Kamaly and 4 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 2 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 2 syntheses or guidelines pooled it, 328 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cancer theranostics.Nature reviews. Cancer · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Towards targeted drugs and next generation of nanomedicines.Beilstein journal of nanotechnology · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Review
  20. Article

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Miles A MillerCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Suresh GaddeLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Christina PfirschkeCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Camilla EngblomCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Melissa M SprachmanCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Rainer H KohlerCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Katherine S YangCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Ashley M LaughneyCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Gregory WojtkiewiczCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Nazila KamalyLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Sushma BhonagiriLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Mikael J PittetCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Omid C FarokhzadLaboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. King Abdulaziz University, Jeddah, Saudi Arabia. rweissleder@mgh.harvard.edu ofarokhzad@bwh.harvard.edu.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. rweissleder@mgh.harvard.edu ofarokhzad@bwh.harvard.edu.
Harvard University · USMassachusetts General Hospital · USCenter for Systems Biology · USKing Abdulaziz University · SA

Funding

StatisticsP50CA086355 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2015
$27.8M
Molecular Regulation of Atherosclerosis Regression - RenewalR01HL084312 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI FISHER, EDWARD A · 2006 to 2024
$11.4M
The Development of Clinical Grade, Targeted Magnetic NanoparticlesU54CA151884 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2010 to 2014
$11.3M
Training Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1M
Quantitative analysis of pharmacological mechanism by intravital imagingR01CA164448 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2011 to 2015
$4.0M
Multiplexed analysis of exosomes in cancer nano therapyR01CA204019 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2016 to 2020
$1.9M
NCI NIH HHS 5P50CA086355NCI NIH HHS P50 CA086355NCI NIH HHS R01 CA164448NCI NIH HHS R01CA164448NCI NIH HHS R01 CA204019NCI NIH HHS T32 CA079443NCI NIH HHS T32 CA 79443.NCI NIH HHS U54 CA151884NCI NIH HHS U54-CA151884NHLBI NIH HHS HL084312NHLBI NIH HHS R01 HL084312
6 · The paper itself

Abstract

Therapeutic nanoparticles (TNPs) have shown heterogeneous responses in human clinical trials, raising questions of whether imaging should be used to identify patients with a higher likelihood of NP accumulation and thus therapeutic response. Despite extensive debate about the enhanced permeability and retention (EPR) effect in tumors, it is increasingly clear that EPR is extremely variable; yet, little experimental data exist to predict the clinical utility of EPR and its influence on TNP efficacy. We hypothesized that a 30-nm magnetic NP (MNP) in clinical use could predict colocalization of TNPs by magnetic resonance imaging (MRI). To this end, we performed single-cell resolution imaging of fluorescently labeled MNPs and TNPs and studied their intratumoral distribution in mice. MNPs circulated in the tumor microvasculature and demonstrated sustained uptake into cells of the tumor microenvironment within minutes. MNPs could predictably demonstrate areas of colocalization for a model TNP, poly(d,l-lactic-co-glycolic acid)-b-polyethylene glycol (PLGA-PEG), within the tumor microenvironment with >85% accuracy and circulating within the microvasculature with >95% accuracy, despite their markedly different sizes and compositions. Computational analysis of NP transport enabled predictive modeling of TNP distribution based on imaging data and identified key parameters governing intratumoral NP accumulation and macrophage uptake. Finally, MRI accurately predicted initial treatment response and drug accumulation in a preclinical efficacy study using a paclitaxel-encapsulated NP in tumor-bearing mice. These approaches yield valuable insight into the in vivo kinetics of NP distribution and suggest that clinically relevant imaging modalities and agents can be used to select patients with high EPR for treatment with TNPs.

Indexed as

NanoparticlesAnimalsAntineoplastic Agents, PhytogenicCell Line, TumorChemistry, PharmaceuticalDisease ProgressionDNA DamageFemaleFerrosoferric OxideFibrosarcomaHumansMacrophagesMagnetic Resonance ImagingMagneticsMice, Inbred BALB CMice, Inbred C57BLAntineoplastic Agents, PhytogenicFerrosoferric OxidePaclitaxelPolyethylene GlycolsPolyglactin 910poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer

Identifiers

PMID26582898
PMCPMC5462466
OpenAlexW2173359203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.